CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.

Saved in:
Bibliographic Details
Title: CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.
Authors: Cohen-Solal JF; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA. joel.cohensolal@abbvie.com., Pohl CS; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA. calvin.pohl@abbvie.com., Cummings SM; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Gygi JP; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Safikhani Z; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Bartocha B; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Buckley CD; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK.; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Dong Y; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Eyerich K; Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany.; Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden., Karsen SD; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Lynch GR; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Macoritto M; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Morisset PA; AbbVie Inc., North Chicago, IL, USA., Nelson OD; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Radstake T; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Rieder F; Department of Inflammation and Immunity, Cleveland Clinic Research, Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Rivas J; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Savaryn JP; AbbVie Inc., North Chicago, IL, USA., Smith KM; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Stulir M; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Szynal C; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Tylek C; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Veldman GM; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Wasserman LG; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Westmoreland S; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Chaudhary N; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA., Staron MM; AbbVie Inc. Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA.
Source: Molecular medicine (Cambridge, Mass.) [Mol Med] 2026 Mar 28; Vol. 32 (1). Date of Electronic Publication: 2026 Mar 28.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 9501023 Publication Model: Electronic Cited Medium: Internet ISSN: 1528-3658 (Electronic) Linking ISSN: 10761551 NLM ISO Abbreviation: Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-3658
DOI:10.1186/s10020-026-01462-z